Poster
119
(#119) Residual Symptom Burden in Patients With Narcolepsy Satisfied With Treatment: Subgroup Analysis From The CRESCENDO Survey
Psych Congress 2025
Abstract: Introduction
People with narcolepsy type 1 (NT1) often experience breakthrough symptoms, despite taking multiple medications. We report a subgroup analysis of respondents from the CRESCENDO survey who reported satisfaction with their current narcolepsy medication to quantify residual symptom burden.
Methods
CRESCENDO was conducted in 2023 in adults with NT1 taking FDA-approved medication for narcolepsy. The survey included assessments of symptom burden and quality of life impact, and was conducted in partnership with patient advocacy organization Narcolepsy Network. Satisfaction was determined on a categorical scale.
Results
Of 203 respondents, 60.6% were taking multiple classes of narcolepsy medication. A majority (63.1%) reported satisfaction with their current treatment(s), 20.2% were neutral, and 16.7% were dissatisfied. Reasons for satisfaction included symptom improvement (70%) and the ability to complete more activities (37%). Of satisfied respondents, 71.9% reported breakthrough cataplexy (10.9% experienced ≥1 attack per day, and 22.8% experienced multiple attacks per week). Additionally, 53.3% reported cataplexy burdens their professional lives, 49.3% their social lives, and 38.7% their day-to-day lives. Other breakthrough symptoms included excessive daytime sleepiness (89.1%), brain fog (73.4%), difficulty concentrating (71.9%), depression (67.2%; Patient Health Questionnaire-8 score ≥5), and cognitive complaints (64.8%; British Columbia Cognitive Complaints Inventory score ≥5).
Conclusion
Respondents satisfied with their current NT1 medication continued to experience substantial symptom burden. These findings reveal a disconnect between patient-reported treatment satisfaction and symptom resolution, possibly reflecting limitations of current therapies, symptom underreporting, or diminished patient expectations. The results suggest a need for enhanced assessment of residual symptoms and novel treatments.
Short Description: CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with current treatment. Despite reporting satisfaction, many continued to experience breakthrough cataplexy, excessive daytime sleepiness, cognitive issues, and depression, which significantly impaired quality of life. These findings highlight a disconnect between treatment satisfaction and symptom resolution, suggesting the need for improved assessment of residual symptoms and novel treatments.
Name of Sponsoring Organization(s): Axsome Therapeutics, Inc., and Narcolepsy Network
People with narcolepsy type 1 (NT1) often experience breakthrough symptoms, despite taking multiple medications. We report a subgroup analysis of respondents from the CRESCENDO survey who reported satisfaction with their current narcolepsy medication to quantify residual symptom burden.
Methods
CRESCENDO was conducted in 2023 in adults with NT1 taking FDA-approved medication for narcolepsy. The survey included assessments of symptom burden and quality of life impact, and was conducted in partnership with patient advocacy organization Narcolepsy Network. Satisfaction was determined on a categorical scale.
Results
Of 203 respondents, 60.6% were taking multiple classes of narcolepsy medication. A majority (63.1%) reported satisfaction with their current treatment(s), 20.2% were neutral, and 16.7% were dissatisfied. Reasons for satisfaction included symptom improvement (70%) and the ability to complete more activities (37%). Of satisfied respondents, 71.9% reported breakthrough cataplexy (10.9% experienced ≥1 attack per day, and 22.8% experienced multiple attacks per week). Additionally, 53.3% reported cataplexy burdens their professional lives, 49.3% their social lives, and 38.7% their day-to-day lives. Other breakthrough symptoms included excessive daytime sleepiness (89.1%), brain fog (73.4%), difficulty concentrating (71.9%), depression (67.2%; Patient Health Questionnaire-8 score ≥5), and cognitive complaints (64.8%; British Columbia Cognitive Complaints Inventory score ≥5).
Conclusion
Respondents satisfied with their current NT1 medication continued to experience substantial symptom burden. These findings reveal a disconnect between patient-reported treatment satisfaction and symptom resolution, possibly reflecting limitations of current therapies, symptom underreporting, or diminished patient expectations. The results suggest a need for enhanced assessment of residual symptoms and novel treatments.
Short Description: CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with current treatment. Despite reporting satisfaction, many continued to experience breakthrough cataplexy, excessive daytime sleepiness, cognitive issues, and depression, which significantly impaired quality of life. These findings highlight a disconnect between treatment satisfaction and symptom resolution, suggesting the need for improved assessment of residual symptoms and novel treatments.
Name of Sponsoring Organization(s): Axsome Therapeutics, Inc., and Narcolepsy Network
